Fabry Disease: Is The Risk of Stroke or Heart Failure Being Properly Managed By Your Medical Team? @checkrare
Fabry Disease: Is The Risk of Stroke or Heart Failure Being Properly Managed By Your Medical Team?  @checkrare
Uploaded September 2026 | Updated November 2026, 2 days ago
This educational program, hosted by Dawn Laney, MS, CGC, CCRC, Genetic Counselor and Program Leader for the Lysosomal Storage Disease Center at Emory University, and Staci Kallish, DO, Associate Professor of Clinical Medicine in the Division of Translational Medicine and Human Genetics at the University of Pennsylvania, examines how best to respond to patients concerns about how their Fabry disease, and its comorbidities, are managed. This program features a dialogue between patients who express their unmet needs, while two renowned Fabry disease experts translate these challenges into actionable clinical strategies.

Topic covered in this video segment is whether the risk of stroke or heart failure is being properly addressed by medical teams.

This educational program is a non-CME activity made possible by an unrestricted grant from Amicus Therapeutics

Faculty
Dawn Laney, MS, CGC, CCRC
Genetic Counselor, Division of Medical Genetics
Program Leader, Lysosomal Storage Disease Center
Emory University School of Medicine
Disclosures
Consulting agreements: Amicus Therapeutics, Chiesi, Sanofi
Member: North American and International Fabry Registry Boards

Staci Kallish, DO
Associate Professor of Clinical Medicine
Division of Translational Medicine and Human Genetics
Perelman School of Medicine, University of Pennsylvania
Disclosures
Research grants: ashibio, Astellas Pharma, , Amicus Therapeutics
Idorsia Therapeutics, Incyte , Ipsen, and Sanofi
Consulting: Amicus Therapeutics, Sanofi
Advisory board: Amicus Therapeutics, Intrabio, Sanofi
Speaking honoraria: Amicus Therapeutics, Astellas, Sanofi

Learning Objectives
Upon completion of this program, participants will be able to:
• Identify and overcome barriers to managing heart concerns in patients with Fabry disease.
Fabry Disease: Is The Risk of Stroke or Heart Failure Being Properly Managed By Your Medical Team?Inhaled Treprostinil Reduces Multiple Disease Progression Events in IPFPrimary IGF-1 DeficiencyFabry Disease: What Symptoms Should Be Better Managed By Your Medical Team?Episode 1: FDA Advisory Board’s Concerns About New Duchenne Drug, Brain Fog in Immune Thrombocyto...Diagnosing Seronegative Myasthenia GravisImportance of Patient Listening in The Development of Rare Disease TreatmentsENERGY Clinical Trial Testing Imaavy (Nipocalimab) in Warm Autoimmune Hemolytic Anemia (wAIHA)What to Expect: 2026 MGFA Scientific SessionBurdensome Symptoms in Fabry DiseasePlasma Proteomics May Predict Disease Manifestations in ALSFirst-Line Therapy Approved for Rare Lung Cancer  | The CheckRare Brief Ep 7
CheckRare |

Fabry Disease: Is The Risk of Stroke or Heart Failure Being Properly Managed By Your Medical Team?

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER